Information  X 
Enter a valid email address

Biogen Inc Ord Shs (0R1B)

Date Time Source Announcement
06 Dec 2018 12:30 pm
GNW
Biogen Exercises Option with Ionis to Develop and Commercialize Investigational Treatment BIIB067 for a Subtype of Familial Amyotrophic Lateral Sclerosis (ALS) Based on Positive Phase 1 Data
29 Nov 2018 12:30 pm
GNW
International Prix Galien Recognizes SPINRAZA® as Best Biotechnology Product
26 Oct 2018 2:15 pm
GNW
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimer’s Disease (CTAD)
25 Oct 2018 1:31 pm
GNW
Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer’s Disease at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Conference
23 Oct 2018 6:00 am
GNW
UCB and Biogen Announce Topline Results from a Phase 2b Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus
18 Oct 2018 12:30 pm
GNW
Biogen to Present Data from Alzheimer’s Disease Portfolio at the 2018 Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
17 Oct 2018 7:00 am
GNW
IMRALDI™, Biogen’s Adalimumab Biosimilar Referencing Humira®, Is Launched in the European Union
11 Oct 2018 12:30 pm
GNW
Biogen Advances Research to Improve Outcomes for Patients With Multiple Sclerosis
06 Oct 2018 12:30 pm
GNW
New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy
03 Oct 2018 12:30 pm
GNW
Biogen to Present Data from its Neurology Pipeline at the 2018 International Congress of Parkinson’s Disease and Movement Disorders (MDS)
02 Oct 2018 12:30 pm
GNW
Biogen Highlights at ECTRIMS 2018 Data on Its Industry-Leading Multiple Sclerosis Portfolio and a Range of Initiatives Aimed at Transforming Patient Care
04 Sep 2018 12:30 pm
GNW
Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction
28 Aug 2018 12:30 pm
GNW
Biogen and Eisai Report Data from Long-Term Extension Phase 1b Study of Investigational Alzheimer’s Disease Treatment Aducanumab
25 Jul 2018 10:08 pm
GNW
Eisai and Biogen Announce Detailed Results of Phase II Clinical Study of BAN2401 in Early Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018
  3:30 pm
GNW
Eisai and Biogen Present Detailed Results From Phase II Clinical Study of Elenbecestat in MCI and Mild to Moderate Alzheimer's Disease at Alzheimer's Association International Conference (AAIC) 2018
18 Jul 2018 12:30 pm
GNW
Data to be Presented From Biogen's Alzheimer's Disease Clinical Development Portfolio at the 2018 Alzheimer's Association International Conference (AAIC)
06 Jul 2018 12:30 am
GNW
Eisai and Biogen Announce Positive Topline Results of the Final Analysis for BAN2401 at 18 Months
28 Jun 2018 9:06 pm
GNW
Biogen Exercises Option to Increase Ownership in Samsung Bioepis
13 Jun 2018 12:30 pm
GNW
Biogen Enhances Commitment to SMA Research with Data Presented at Annual SMA Conference
07 Jun 2018 12:30 pm
GNW
Biogen Enters Exclusive Option Agreement to Acquire TMS' Phase 2 Asset for Acute Stroke
31 May 2018 12:30 pm
GNW
Biogen Appoints Daniel Karp as EVP, Corporate Development
08 May 2007 7:00 am
RNS
Biogen Idec and Vernalis
  7:00 am
RNS
Biogen Idec and Vernalis
28 Sep 2006 2:31 pm
BUS
Research Update
14 Apr 2005 7:00 am
BUS
Positive One-Year Data From SENTINEL Trial
28 Feb 2005 1:16 pm
BUS
Biogen Idec and Elan Announce Voluntary Suspension
  1:16 pm
BUS
Biogen Idec and Elan Announce Voluntary Suspension
05 Jan 2005 7:00 am
RNS
Agreement with Biogen Idec
  7:00 am
RNS
Agreement with Biogen Idec
21 Dec 2004 1:08 pm
BUS
Biogen Idec and Elan Announce Head-to-Head
18 Aug 2004 7:45 am
PRN
Regulatory Update
 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t